Spero Therapeutics Stock Rises Above 50-Day Average

Should Investors Sell Shares as the Biotech Stock Surges?

Apr. 7, 2026 at 8:12am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of gears, levers, and other heavy industrial banking equipment, conveying the complex mechanics and machinery underlying stock market fluctuations.The complex financial infrastructure behind Spero Therapeutics' stock price movements reflects the volatility and uncertainty facing the biotech industry.Boston Today

Shares of Spero Therapeutics (NASDAQ:SPRO), a Boston-based biopharmaceutical company focused on developing novel antibiotics, have risen above their 50-day moving average, prompting questions about whether it's time for investors to sell.

Why it matters

Crossing above the 50-day moving average is often seen as a bullish signal, but it can also indicate the stock may be overbought and due for a pullback. Investors will be watching to see if Spero Therapeutics can maintain its momentum or if the stock price will retreat.

The details

Spero Therapeutics' stock price reached as high as $2.61 on Monday, surpassing its 50-day moving average of $2.35. The company's shares last traded at $2.61, with trading volume of 478,730 shares. Spero is developing an oral carbapenem antibiotic called tebipenem HBr to treat complicated urinary tract infections.

  • Spero Therapeutics' stock price crossed above its 50-day moving average on Monday, April 7, 2026.
  • The company reported quarterly earnings on March 26, 2026.

The players

Spero Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies to address multidrug-resistant bacterial infections. The company is headquartered in Boston, Massachusetts.

Tebipenem HBr

Spero Therapeutics' lead drug candidate, an oral carbapenem antibiotic being developed to treat complicated urinary tract infections caused by resistant Gram-negative pathogens.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching to see if Spero Therapeutics can maintain its stock price above the 50-day moving average, or if the shares will retreat in the coming days and weeks.

The takeaway

Spero Therapeutics' stock price surge above its 50-day moving average highlights the volatility and uncertainty surrounding the company's prospects, as analysts remain divided on whether the biotech stock is a buy or a sell.